CING stock icon

Cingulate
CING

$0.7
1.41%
 

About: Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Employees: 13

0
Funds holding %
of 6,689 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

343% more capital invested

Capital invested by funds: $29.1K [Q4 2023] → $129K (+$99.8K) [Q1 2024]

80% more funds holding

Funds holding: 5 [Q4 2023] → 9 (+4) [Q1 2024]

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

3.76% more ownership

Funds ownership: 0.4% [Q4 2023] → 4.16% (+3.76%) [Q1 2024]

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$8
1,043%
upside
Avg. target
$8
1,043%
upside
High target
$8
1,043%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
1,043%upside
$8
Buy
Maintained
5 Jan 2024

Financial journalist opinion